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ABSTRACT
Segmental multi-frequency bioelectrical impedance analysis (SMF-BIA) has
been shown to be a valid, more portable, and less expensive alternative to dual energy
x-ray absorptiometry (DXA) for the measurement of appendicular lean mass (ALM) in
several populations. However, few studies have examined the validity of SMF-BIA
specifically among populations of older women classified as sarcopenic or dynapenic.
The aim of this cross sectional study was to investigate the accuracy of SMF-BIA
compared to the gold standard DXA for the measurement of ALM among sarcopenic
and/or dynapenic older women. Physical function, ALM, strength, and
anthropometric tests were performed to determine the presence of sarcopenia and/or
dynapenia in a sample of 25 older (72.3 ± 4.6 years) women using established
sarcopenia classification criteria. Estimation of ALM using SMF-BIA and DXA were
performed under standardized testing conditions. Both techniques were administered
within the same hour with participants adequately hydrated, fasted, following urine
elimination, and while wearing hospital scrubs. A Pearson correlation coefficient was
used to determine a relationship between the two methods for ALM and agreement
between the two techniques was assessed using a Bland-Altman plot method.
Statistical significance was set at p < 0.05. A significant and strong correlation was
observed between the two techniques with a Pearson’s correlation coefficient of 0.88
(95% CI= 0.75 to 0.95; p < 0.001). The Bland-Altman plot showed a mean difference
of 0.5 kg and an indication of overall agreement between techniques. However, SMFBIA overestimated ALM for one participant (-2.9 kg, 95% CI= -3.76 to -2.03) and
underestimated ALM for another participant (1.8 kg, 95% CI= 0.98 to 2.71) compared

to DXA. The findings indicate overall agreement between SMF-BIA and DXA for the
estimation of ALM among older women with characteristics of sarcopenia, but SMFBIA may overestimate or underestimate ALM in some individuals. These data
suggest that SMF-BIA may be an acceptable alternative to DXA for the assessment of
ALM in older women with characteristics of sarcopenia.
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PREFACE
This thesis is written to comply with the University of Rhode Island graduate
school manuscript format. The thesis document contains one manuscript: Validation
of Bioelectrical Impedance Analysis for the Measurement of Appendicular Lean Mass
in Older Women. The manuscript has been written in a form formatted for publication
in the International Journal of Body Composition Research.
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ABSTRACT
Objective: Segmental multi-frequency bioelectrical impedance analysis (SMF-BIA)
has been shown to be a valid, more portable, and less expensive alternative to dual
energy x-ray absorptiometry (DXA) for the measurement of appendicular lean mass
(ALM) in several populations. However, few studies have examined the validity of
SMF-BIA specifically among populations of older women classified as sarcopenic or
dynapenic. The aim of this cross sectional study was to investigate the accuracy of
SMF-BIA compared to the gold standard DXA for the measurement of ALM among
sarcopenic and/or dynapenic older women.
Methods: Physical function, ALM, strength, and anthropometric tests were performed
to determine the presence of sarcopenia and/or dynapenia in a sample of 25 older (72.3
± 4.6 years) women using established sarcopenia classification criteria. Estimation of
ALM using SMF-BIA and DXA were performed under standardized testing
conditions. Both techniques were administered within the same hour with participants
adequately hydrated, fasted, following urine elimination, and while wearing hospital
scrubs. A Pearson correlation coefficient was used to determine a relationship
between the two methods for ALM and agreement between the two techniques was
assessed using a Bland-Altman plot method. Statistical significance was set at p <
0.05.
Results: A significant and strong correlation was observed between the two
techniques with a Pearson’s correlation coefficient of 0.88 (95% CI= 0.75 to 0.95; p <
0.001). The Bland-Altman plot showed a mean difference of 0.5 kg and an indication
of overall agreement between techniques. However, SMF-BIA overestimated ALM
2

for one participant (-2.9 kg, 95% CI= -3.76 to -2.03) and underestimated ALM for
another participant (1.8 kg, 95% CI= 0.98 to 2.71) compared to DXA.
Discussion: The findings indicate overall agreement between SMF-BIA and DXA for
the estimation of ALM among older women with characteristics of sarcopenia, but
SMF-BIA may overestimate or underestimate ALM in some individuals. These data
suggest that SMF-BIA may be an acceptable alternative to DXA for the assessment of
ALM in older women with characteristics of sarcopenia.
Keywords: Sarcopenia, DXA
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INTRODUCTION
Sarcopenia is defined as the progressive loss of muscle mass, physical
function, and strength (i.e. dynapenia) which accelerates with aging [1–3]. Sarcopenia
is associated with several adverse health outcomes among older adults including
frailty, weakness, functional decline, increased risk of falls and fractures, and loss of
independence [1,2]. In the year 2000, estimated healthcare costs associated with
sarcopenia were $12.6 billion for older men, and $29.5 billion for older women [4].
The economic burden associated with sarcopenia is likely far higher today particularly
in women, as they have a greater life expectancy and risk for functional impairment
compared to men [5]. Although a universally accepted definition for sarcopenia is
currently lacking, several working groups have convened to establish operational
criteria for classification including measures of physical function, strength, and muscle
mass.
While a wide range of techniques are available for assessing muscle mass, dual
energy X-ray absorptiometry (DXA) is considered as the gold standard in research and
clinical practice to determine appendicular lean mass (ALM) despite its limitations
including exposure to radiation, expense, and lack of portability [2,6–8]. Thus, is it
critical to find alternative methods for ALM assessment.
The use of segmental multi-frequency bioelectrical impedance analysis (SMFBIA) for the measurement of muscle mass has been accepted as a valid, more portable,
and less expensive alternative in several populations [9–12] including older women
[13,14]. While one study has validated the use of SMF-BIA for the estimation of ALM
among a general population of older women [13], the device has not yet been
4

validated for the assessment of ALM and its application to sarcopenia identification
based on several accepted definitions. Thus, the purpose of this investigation was to
assess whether SMF-BIA would accurately quantify ALM compared to DXA among a
population of older women with characteristics of sarcopenia and/or dynapenia. It was
hypothesized that SMF-BIA would be in agreement with DXA for the estimation of
ALM. A secondary aim was to examine if SMF-BIA similarly classifies older women
as sarcopenic compared to DXA based on ALM compared to height or body mass
index (BMI) using established cut-points.

5

METHODS
Study Design
The study utilized a cross-sectional design to compare differences between
SMF-BIA and DXA for the estimation of ALM among 25 older women pre-screened
for the presence of sarcopenia and/or dynapenia (reduced strength). The participants
were pre-screened for entry into a 12-week University of Rhode Island Institutional
Review Board approved, Resistance Exercise Study to Reclaim Lean Muscle and
Strength (URI RESTORE ME Project: IRB # HU1415-168). The two techniques
being compared for this study were performed at baseline of the URI RESTORE ME
project.
Participants
Community dwelling women (n = 25) aged 65 to 84 years were recruited from
Rhode Island via flyers, newspaper ads, press releases, and by word of mouth within
local senior centers. All women initially eligible based on information provided
during a telephone screening were invited to an onsite orientation and pre-screening
assessment. During pre-screening, all women provided written informed consent and
were evaluated for the presence of sarcopenia and/or dynapenia determined from the
assessment of lean mass, height, weight, grip strength, single chair stand, and gait
speed based on the European Working Group on Sarcopenia in Older People
(EWGSOP) and the Foundation for the National Institute of Health Sarcopenia Project
(FNIHSP) criteria. The pre-screening visit determined that 38 participants were
eligible based on the sarcopenia criteria. Although eligible, 13 participants were
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subsequently eliminated from the final cohort due to questions of time commitment or
orthopedic concerns that would limit full participation in the intervention phase of the
project. Figure 1 summarizes each phase of study recruitment.
Outcome Measures
All testing sessions were standardized with participants arriving in the morning
in a fasted state. Participants were instructed to arrive well hydrated and having not
exercised. Both techniques for measuring body composition were performed on the
same day, within the same hour, and following urine elimination. All participants
were dressed in hospital scrubs for both methods.
Appendicular Lean Mass: ALM was estimated using fan-beam technology (GE
Lunar iDXA, Waukesha, WI). The DXA scans were performed using a standardized
procedure for patient positioning by a licensed radiology technician. The DXA scans
provided estimations of ALM defined as the total skeletal muscle mass from the right
arm, left arm, right leg, and left leg measured in kilograms.
In addition to DXA, a SMF-BIA was used to estimate segmental muscle mass
whereby ALM could then be calculated. The InBody 570 Biospace device (Biospace
Co, Ltd, Korea) was used according to the manufacturer’s guidelines during both the
pre-screening assessment (to determine sarcopenia status) and baseline testing to
assess ALM. Body composition is estimated via SMF-BIA using the difference of
conductivity of various tissues due to the differences in their biological characteristics.
The risk of adverse events is low using SMF-BIA and its use has been performed
safely on older adults in other studies [15]. As a precaution, women with a cardiac
pacemaker or internal defibrillator were not tested.
7

Sarcopenia Status: Prior to the collection of baseline testing data, participants
completed pre-screening to determine their eligibility as presenting with sarcopenia
and/or dynapenia. An algorithm for determining eligibility was developed based on a
combination of both the EWGSOP and FNIHSP working definitions for sarcopenia.
Initial ALM estimates using SMF-BIA in addition to outcomes of physical function
using the gait speed, single chair stand, and grip strength tests were included in the
algorithm. The cut-points established for each criteria included an ALM < 5.67 kg/m2
or ALM/BMI < 0.512, a grip strength < 20 kg or inability to complete a single chair
stand, and a gait speed < 0.8 m/s [2,16]. Women selected were classified as having
low lean mass (LM), low strength, low function (slow gait), or all three characteristics.
Physical Function: As part of the short physical performance battery (SPPB)
of tests, usual gait speed was measured during pre-screening and during baseline to
assess physical function and as a fundamental criterion for defining sarcopenia status.
Gait speed has been suggested as being included in routine evaluations as the sixth
vital sign [7] as it is a strong predictor of major health outcomes and survival in older
adults [6]. The EWGSOP, International Working Group (IWG), and FNIHSP are all
in agreement that a gait speed < 0.8 m/s should be used as a cut-point for identifying
sarcopenia in older adults [2,16,18]. Standardized protocols were utilized for
administration of the gait speed test which required participants to walk 4 meters at a
usual pace [19]. The test was repeated twice with the faster of the two trials recorded
in seconds.
Muscle Strength: Grip strength is reliable, valid, and simple to administer in
both clinical and community settings and is a predictor of mobility impairment
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[20,21]. Grip strength was tested during pre-screening and during baseline using a
handgrip dynamometer (Jaymar Hydraulic Dynamometer, J.A. Preston, Corp.,
Jackson, MS). The test was performed with the participant seated in a chair with the
elbow bent to 90 degrees using a standardized protocol [22]. The dynamometer was
set accordingly based on each individual’s hand size so that the second knuckle of all
four fingers rested flat on the handle. Two trials were performed on each hand and the
highest score was recorded in kilograms without accounting for hand dominance.
Grip strength values < 20 kg were also used as criteria for determining the presence of
sarcopenia and/or dynapenia. Participants also completed a single chair stand test to
assess lower body strength using a standardized protocol [23]. The test required that
the participant rise from a chair with the arms crossed over the chest and with both
feet flat on the floor. The ability or inability to rise from the chair was recorded and
used to classify individuals as weak (i.e. dynapenia).
Anthropometrics: Each participant’s height and weight were measured twice
and the average of the two readings were used. Height and weight were measured
with each participant barefoot and wearing hospital scrubs. Height was measured
using a wall mounted stadiometer and weight was recorded using the InBody 570
SMF-BIA device. From these measurements, BMI was calculated by dividing the
participants weight in kilograms by their height in meters squared.
Other Measures
Physical Activity: To assess each participant’s physical activity level, the Yale
Physical Activity Survey (YPAS) was administered during baseline testing. The
YPAS quantifies the type and intensity of physical activity among older adults
9

estimating total energy expenditure (kcals/week) and a total activity summary index.
The YPAS has been shown to be a valid measurement for the assessment of physical
activity among older adults [24]. The YPAS was used to describe physical activity
patterns of the participant population.
Dietary Intake: Participants completed a Dietary Screening Tool (DST)
developed for older adults at baseline to assess dietary patterns [25]. The DST
identifies 3 levels of nutritional risk: at risk (< 60), at possible risk (60 to 75), and not
at risk (> 75) [26]. Nutritional risk assessed with the DST was used to describe the
participant population.
Statistical Analysis
Estimated between-group differences were calculated for the primary
outcomes, and a paired t-test was used to compare differences in estimated ALM by
SMF-BIA and DXA. A previous study comparing SMF-BIA and DXA among frail
women 75 years or older demonstrated an overall mean difference for ALM between
the two techniques as 0.08 ± 0.05 kg [13]. Based on the findings of this study, a
sample size of 16 were required to provide sufficient power (0.80) and alpha at 0.05.
Clinical and demographic characteristics of the participants are expressed as
mean ± standard deviation. A Shapiro-Wilk test was performed to verify that data for
the primary outcome variables were within normal distribution. To determine the
strength of the relationship between the two variables, a Pearson moment correlation
coefficient was performed. To test the primary hypothesis, a Bland-Altman method
was employed to compare agreement between DXA and SMF-BIA whereby the
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differences in techniques are plotted against the averages of the two techniques [27].
To test the secondary hypothesis, a Fisher’s exact test was used to compare sarcopenia
status based on ALM between the two techniques. Statistical analyses were performed
using SAS version 9.2 (SAS Institute Inc., Cary, NC, USA).
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RESULTS
A total of 25 female participants with a mean age of 72.3 ± 4.6 years were
enrolled in this study. Demographic characteristics, anthropometric measures,
indictors of physical functioning, physical activity, and dietary habits of the study
population are summarized in Table 1.
A significant difference (p = 0.0145) was observed between DXA and SMFBIA for the measurement of ALM by a mean of 0.5 kg for each participant.
Additionally, a 4.3% error of ALM by SMF-BIA was observed compared to DXA as
the gold standard (p = 0.0162). A significant and strong positive correlation was
observed between SMF-BIA and DXA as indicated by a Pearson’s correlation
coefficient of 0.88 (95% CI= 0.75 to 0.95, p < 0.001) highlighted in Figure 2. In
addition, agreement between the two methods was assessed using a Bland-Altman plot
(Figure 3). A mean difference of 0.5 kg (95% CI= -1.02 to -0.02) indicates overall
agreement between SMF-BIA and DXA. However, SMF-BIA overestimated ALM
for one participant (-2.9 kg, 95% CI= -3.76 to -2.03) and underestimated ALM for
another participant (1.8 kg, 95% CI= 0.98 to 2.71) compared to DXA.
When comparing sarcopenia status based on ALM measured by SMF-BIA and
DXA, the Fisher’s exact test indicates a significant difference (p < 0.001) between the
two techniques when using both the EWGSOP and FNIHSP criteria. Of the 25
women found to demonstrate characteristics of sarcopenia and/or dynapenia based on
EWGSOP criteria during pre-screening, SMF-BIA identified less participants (n = 7)
as sarcopenic compared to DXA (n = 11). While SMF-BIA and DXA similarly
identified the normal and pre-sarcopenic participants, DXA was able to identify more
12

participants as having sarcopenia based on current EWGSOP criteria (Table 2).
Similarly, DXA was able to identify more participants as having low lean mass (n = 9)
compared to SMF-BIA (n = 6) based on FNIHSP criteria (Table 3).
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DISCUSSION
The results of this study indicate overall agreement between SMF-BIA and
DXA for the estimation of ALM among older women with characteristics of
sarcopenia and/or dynapenia. A significant and strong correlation (r = 0.88) and the
lack of significant difference between the two techniques indicates acceptability of
SMF-BIA compared to DXA. The Bland Altman plot provided a visual judgement of
agreement between techniques with a mean overestimation of ALM by SMF-BIA of
0.5 kg. While most participants fell within the 95% limits of agreement, two outliers
were identified. The plot indicates that SMF-BIA overestimated ALM but was not
statistically different from DXA. The results of the present study are in line with
previous studies which support that SMF-BIA is a valid, more portable, and affordable
alternative to DXA for the estimation of ALM [7,9,10,13,14].
While the study indicates that SMF-BIA is a valid alternative to DXA, DXA
appears to be more reliable for assessing ALM for diagnosing sarcopenia. Criteria for
sarcopenia classification required that the participants ALM be < 5.67 kg/m2 or
ALM/BMI < 0.512 in combination with weak grip strength (< 20 kg) and/or slow gait
speed (< 0.8 m/s). These findings suggest that SMF-BIA may overestimate ALM just
enough to allow some participants to be above the sarcopenia ALM cut-off value.
While the grip strength and gait speed functional outcomes stand alone to identify
individuals at risk for sarcopenia, DXA is the most reliable method for identifying
sarcopenic females based on ALM. Although overall agreement between SMF-BIA
and DXA for the estimation of ALM was observed in this study, investigators should
use caution when using some impedance models for diagnosing sarcopenia.
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In agreement with these findings, previous studies have demonstrated that
SMF-BIA is a valid alternative to DXA for the estimation of ALM among healthy
adult [9,10] and older female participants [13,14]. Andersen et al. [10] determined
that similar SMF-BIA devices, namely the InBody 520 and 720, were valid for the
estimation of ALM among healthy young women between the ages of 18 and 49 years.
While both devices were strongly correlated to DXA, (r = 0.62 - 0.87) the conclusions
were that SMF-BIA underestimated ALM by approximately 1.0 kg in the 25 female
participants. Similar results were observed by Leahy et al. [9] with BIA
underestimating arm and leg fat free mass by 0.2 kg (2.4 %) and 0.8 kg (3.4 %),
respectively, in men and 0.2 kg (4.5 %) and 0.7 kg (4.4 %), respectively, in women (p
< 0.001). Another similar study identified SMF-BIA as an appropriate alternative to
DXA for the estimation of fat mass, percent body fat, and total lean mass, but not for
the evaluation of ALM among a healthy adult population between 18 and 85 years
[12]. Although the present study identifies the InBody 570 SMF-BIA device to be a
valid alternative to DXA, the tendency for SMF-BIA to overestimate or underestimate
ALM in some participants did occur as consistent with previous study findings.
Conflicting results regarding the agreement between SMF-BIA and DXA
specifically for the measurement of ALM among elderly women have also been
reported in other similar studies [7,13,14]. Buckinx et al. [7] observed low agreement
between the two methods among approximately 25 women in the subcategory of
participants over the age of 65 (n = 48) using a Bland-Altman plot method. The study
reported a tendency for SMF-BIA to overestimate ALM by approximately 1.75 kg [7].
Other studies investigating older women report acceptable accuracy of SMF-BIA
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compared to DXA for the estimation of ALM. Among an older female Japanese
population (n = 330) aged 65 to 87 years old, SMF-BIA tended to underestimate ALM
by 1.59 kg (95% CI= 1.49 to 1.68) [14]. Segmental multi-frequency BIA also
provided acceptable accuracy for the estimation of ALM among frail women 75 years
and older with a tendency to underestimate ALM (r = -1.42, p < 0.01) [13]. In the
present study, despite significant differences in sarcopenia definitions between SMFBIA and DXA, the Bland-Altman plot indicated overall agreement between the two
methods for the estimation of ALM with a mean difference of 0.5 kg among the older
female participants.
This study has both strengths and weaknesses. The main strength was the use
of standardized testing conditions. All participants were instructed to arrive for testing
fasted, well hydrated, having not exercised, and following urine elimination. These
confounding variables were well-controlled in addition to SMF-BIA and DXA being
performed within the same hour. Hydration status upon arrival for testing was
assessed based on self-report in addition to a normal ratio of extracellular water to
total body water content (ECW/TBW) estimated by SMF-BIA. All participants
ECW/TBW ratios were within the normal range of 0.36 to 0.39 as defined by the
InBody manufacturer. The use of DXA as the gold standard method for body
composition analysis by which SMF-BIA could be compared was an additional
strength of the present study.
Potential limitations include the small sample size and homogeneity of the
participant population as the results may not be generalizable to other populations. A
larger sample size of older women including those from different racial, ethnic, and
16

socioeconomic backgrounds could have demonstrated more similarity between SMFBIA and DXA using Fisher’s exact analysis. The present study was limited to
investigating the validity of only one of many SMF-BIA devices, the InBody 570.
Additionally, the study was cross sectional therefore, future studies should examine
changes in ALM longitudinally and following interventions.
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CONCLUSION
While previous studies have investigated the validity of SMF-BIA for
estimation of ALM compared to DXA among older women, this is the first study to
validate SMF-BIA in a population of older women who present with sarcopenia and/
or dynapenia. In conclusion, the present study confirmed overall agreement between
SMF-BIA and DXA for the measurement of ALM among older women who present
with characteristics of sarcopenia and/or dynapenia based on current definitions. It is
possible however, that SMF-BIA may overestimate or underestimate ALM in some
participants. While SMF-BIA is an acceptable, less expensive, and more portable
alternative to DXA for measuring ALM, future studies are required using other
devices and larger samples to justify that SMF-BIA is more realistic for clinical and
epidemiological identification of sarcopenia based on current definitions.
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TABLES

Table 1. Baseline Participant Characteristics
Mean (SD)

Minimum

Maximum

Age

72.3 (4.6)

66

81

Weight (kg)

65.3 (13.5)

47

100.7

Height (cm)

159.8 (5.2)

149.9

168.9

BMI (kg/m2)

25.7 (5.8)

18.9

42

% Body Fat

42.5 (6.3)

28.1

55.8

Gait Speed
(meters/second)
Grip Strength (kg)

0.97 (0.12)

0.68

1.18

16.6 (3.7)

10

28

6,912 (3,270)

1,183

13,350

49.6 (22.1)

16

103

73.3 (6.4)

52

82

Physical Activity
(kcals/week)
Physical Activity
Index
Dietary Patterns

*Abbreviation: BMI, Body Mass Index
*Physical Activity and dietary patterns derived from the Yale Physical Activity Survey
*Dietary Patterns derived from the Dietary Screening Tool
< 60 = at risk, 60-75 = at possible risk, >75 = not at risk (Bailey et al., 2009) 26
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Table 2. Fisher’s Exact Test for Sarcopenia Classification Based on European
Working Group on Sarcopenia in Older People (EWGSOP) Definition Comparing
Segmental Multi-frequency Bioelectrical Impedance (SMF-BIA) and Dual Energy Xray Absportiometry (DXA)

SMF-BIA
Normal
SMF-BIA PreSarcopenia
SMF-BIA
Sarcopenia
SMF-BIA
Weak
Total

DXA
DXA PreNormal Sarcopenia
3
0

DXA
Sarcopenia
0

DXA
Weak
0

Total

0

1

0

0

1

0

0

7

0

7

0

0

4

10

14

3

1

11

10

25

*Normal = ALM > 5.67 kg/m2, Grip Strength > 20 kg, and Gait Speed > 0.8 m/s
*Pre-Sarcopenia = ALM <5.67 kg/m2, Grip strength > 20 kg, and Gait Speed > 0.8m/s
*Sarcopenia = ALM <5.67 kg/m2 and Grip < 20 kg or Gait Speed < 0.8 m/s
*Weak = ALM > 5.67 kg/m2 and Grip < 20 kg
NOTE: Significant difference between definitions (p < 0.001)
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3

Table 3. Fisher’s Exact Test for Sarcopenia Classification Based on the Foundation
for the National Institute of Health Sarcopenia Project (FNIHSP) Definition
Comparing Segmental Multi-frequency Bioelectrical Impedance (SMF-BIA) and Dual
Energy X-ray Absportiometry (DXA)

SMF-BIA Low
Lean
SMF-BIA
Normal
SMF-BIA
Weak
Total

DXA
Low
Lean
6

DXA
Normal

DXA
Weak

Total

0

0

6

3

7

0

10

0

0

9

9

9

7

9

25

*Normal = ALM > 15.02 kg or ALM/BMI > 0.512 and Grip Strength > 16 kg
*Low Lean = ALM < 15.02 kg or ALM/BMI < 0.512 and Grip > 16 kg
*Weak = ALM > 15.02 kg or ALM/BMI > 0.512 and Grip <16 kg
NOTE: Significant difference between definitions (p < 0.001)
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FIGURES

Figure 1. Study Flow Chart
Phone Screened for
Initial Eligibility
(n=160)

Excluded (n=99)
-Did not meet eligibility
criteria (n=70)
-Unavailable for time
commitment (n=9)
-Not interested (n=20)

Pre-Screened for Eligiblity (n=61)
-Provided Informed Consent
-Assessment of body composititon,
grip strength, single chair stand, and
gait speed

Excluded (n= 23)
-Did not meet sarcopenia or
dyanapenia guidelines

Eligible (n=38)
-Investigator Review
for selection

Baseline Tested
(n=25)
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Figure 2. Pearson’s Correlation Coefficient Between Segmental Multi-frequency
Bioelectrical Impedance (SMF-BIA) and Dual Energy X-ray Absorptiometry (DXA)
for the Measurement of Appendicular Lean Mass (ALM)

r = 0.88
p < 0.001

*A significant and strong positive correlation was observed between SMF-BIA and DXA with a
correlation coefficient of 0.88 (95% CI= 0.75 to 0.95, p < 0.001).
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Figure 3. Bland-Altman Plot Comparing Appendicular Lean Mass (ALM) by
Segmental Multi-frequency Bioelectrical Impedance (SMF-BIA) and Dual Energy Xray Absorptiometry (DXA)

*A mean difference of 0.5 kg (95% CI= -1.02 to -0.02) indicates overall agreement between
SMF-BIA and DXA.
*SMF-BIA overestimated ALM for one participant (-2.9 kg, 95% CI= -3.76 to -2.03) and
underestimated ALM for another participant (1.8 kg, 95% CI= 0.98 to 2.71) compared to
DXA.
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APPENDICES
Appendix A: Review of the Literature

Abstract
The loss of muscle mass associated with advancing age, termed sarcopenia,
contributes to the development of physical disability and mobility limitation. Women
are at a greater risk for developing physical disability compared to men as patterns of
functional impairment related to the loss of muscle and strength (i.e. dynapenia) differ
between genders. Although a universally accepted definition for sarcopenia is lacking,
several working groups have established criteria based on low appendicular lean mass
(ALM) and poor physical function. While dual energy x-ray absorptiometry (DXA) is
considered as the gold standard method for measuring ALM, several studies have
validated the use of segmental multi-frequency bioelectrical impedance (SMF-BIA) as
a more portable alternative. No study to date has assessed the accuracy of SMF-BIA
among older women who present with characteristics of sarcopenia and/or dynapenia.

Introduction
Sarcopenia is defined as the progressive loss of muscle mass, physical
function, and strength (i.e. dynapenia) which accelerates with advancing age.1–3 The
mechanisms for sarcopenia are multifactorial and include physical inactivity,
malnutrition, hormonal changes, denervation of motor units, and the conversion of fast
type II muscle fibers to slow type I muscle fibers, among others.2,4 As a natural
28

process of aging, muscle mass declines by approximately 1 to 2% per year after age 50
contributing to the loss of strength at an even greater rate.1,5,6 Muscle strength has
been reported to decline 2 to 5 times faster than muscle mass with age contributing to
poor physical function, mobility limitation, and disbaility.7–9 Sarcopenia is associated
with several adverse health outcomes among older adults including frailty, weakness,
functional decline, increased risk of falls and fractures, and loss of independence.1,2
Moreover, in the year 2000, estimated healthcare costs associated with sarcopenia
were $12.6 billion for older men, and $29.5 billion for older women.10 The economic
burden associated with sarcopenia is likely far higher today particularly in women, as
they have a greater life expectancy and risk for functional impairment compared to
men.11,12
Although there is currently no universal definintion for identifying sarcopenic
individuals, several working groups have established cut-points for low lean mass in
addition to markers of reduced physical functioning and muscle strength. While early
definitions were based exclusively on muscle mass compared to a healthy reference
population,13 the current definitions also consider performance criteria. The European
Working Group on Sarcopenia in Older People (EWGSOP), the Foundation for the
National Intistutes of Health Sarcopenia Project (FNIHSP), and the International
Working Group (IWG) are all in agreement that ALM in combination with weak grip
strength and or slow gait speed be present to confirm sarcopenia status.
While a wide range of techniques are available for assessing muscle mass,
DXA is considered as the gold standard in research and clinical practice to determine
ALM despite its limitations including exposure to radiation, expense, and lack of
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portability.2,14,15,4 Thus, is it critical to find alternative methods for ALM assessment.
The use of segmental multi-frequency bioelectrical impedance analysis (SMF-BIA)
for the measurement of muscle mass has been accepted as a valid, more portable, and
less expensive alternative in several populations16–19 including older women.20,21
While some studies have validated the use of SMF-BIA for the estimation of ALM
among older women,20 the device has not yet been validated for the assessment of
sarcopenia based on current international definitions.

Sarcopenia in Older Women
Women represent the largest proportion of the elderly, and their patterns of
functional impairment related to declines in muscle mass and strength differ from
men.12 Women are at a greater risk for developing decreased muscle strength
(dynapenia) and sarcopenia with aging which also increases their risk for mortality
compared to men as they have more fat, lower absolute muscle mass, and less
strength.1,22 The earlier development of muscle weakness observed in women
compared to men can be partially explained by menopause as a reduction in the sexhormone estrogen is associated with loss of bone mass and strength.11,23 Changes in
the sex hormones estrogen and progesterone begin a decade or more prior to
menopause, which may accelerate the morphological changes in skeletal muscle
characteristic of sarcopenia. Consequently, post-menopausal women present with half
the concentration of estrogen observed before menopause thus increasing their
incidence of sarcopenia.24
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Women also experience earlier declines in muscle power at a rate of 3 to 4%
faster than strength compared to men.24 Early declines in muscle power, defined as
the ability to perform muscular work per unit of time could explain the variance in
poorer physical function and subsequent disability.24,25 A longitudinal study followed
545 high-functioning women aged 75 years and older over a seven-year period to
determine which baseline activities of daily living were most strongly predictive of
future disability. Women with poor mobility measured by time to complete five chair
stands, gait speed, and number of steps to walk 6 meters had odds ratios (95% CI)
equal to 7.62 (3.86, 15.04), 6.31 (3.26, 12.19) and 5.31 (2.43, 11.59), respectively, for
developing disability while women with poor grip strength had 2.81 (1.43, 5.52) times
the risk of developing disability.12 Given that women experience a greater life
expectancy as well as greater functional impairment associated with muscle weakness,
early identification of muscle loss using accurate and clinically available techniques is
especially important so that appropriate interventions can be delivered to reduce
adverse health outcomes and improve quality of life.11

Working Definitions for Sarcopenia
Screening individuals for clinically significant sarcopenia has presented as a
major challenge for the justification of intervention strategies that could reduce
disability among older adults without a universally accepted definition. As a result,
several working groups have convened to establish criteria to identify individuals at
risk in order to prevent adverse events associated with reduced lean mass (LM) and
physical function.13,26 Muscle mass can be quantified using DXA, SMF-BIA, and
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anthropometry while muscle strength can be measured most effectively by testing
handgrip strength using a handheld dynamometer.27 In clinical practice, physical
performance is measured using the short physical performance battery (SPPB) of tests,
the get up and go test, and gait speed. The most prominent statements defining
sarcopenia based on low muscle mass and physical function have come from the
European Working Group on Sarcopenia in Older People (EWGSOP), International
Working Group (IWG), and the Foundation for the National Institutes of Health
Sarcopenia Project (FNIHSP). While early definitions were based exclusively on
muscle mass compared to a healthy reference population, the current definitions also
consider performance criteria.13
The EWGSOP algorithm requires that low muscle mass accompanied by either
low grip strength, slow gait speed, or a combination of all three be present for
classification of pre-sarcopenia, sarcopenia, or severe sarcopenia.2,13 The EWGSOP
defines low muscle mass as an ALM in kilograms relative to height squared (kg/m2)
less than 7.23 kg/m2 in men and less than 5.67 kg/m2 in women. Their cutoff values
for low grip strength are set at less than 30 kg in men and less than 20 kg in women.
In order to be considered slow, and individual must present with a gait speed less than
0.8 meters per second (m/s). Based on the results from screening of the above
mentioned criteria, the severity of sarcopenia may be determined. Pre-Sarcopenia is
defined by low muscle mass without low muscle strength whereas severe sarcopenia is
defined by demonstrating all three criteria. Individuals with sarcopenia present with
low muscle mass in combination with either low grip strength or slow gait speed.
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The International Working Group defines sarcopenia as the age related loss of
skeletal muscle mass and function caused by several factors including disuse, altered
endocrine function, chronic diseases, inflammation, insulin resistance, and nutritional
deficiencies which contribute to disability, hospitalization, and death.28 The group
considers that all older patients who present with observed decrements in physical
function, strength, and overall health be evaluated. Their diagnosis of sarcopenia is
based on the presence of low whole body or ALM in combination with poor physical
functioning. Similar to the EWGSOP criteria, the IWG confirms diagnosis of
sarcopenia based on the same ALM criteria however, their cut-points are less
conservative with slow gait speed defined as less than 1.0 m/s.28
Rather than define sarcopenia, the FNIH have proposed a two-step clinical
paradigm to identify individuals with low muscle strength and low muscle mass by
first screening for mobility impairment and low muscle strength measured by gait
speed and grip strength, respectively.13,29 The FNIHSP recommends that individuals
be identified using either “weak with low LM” or “weak and slow with low LM”
rather than use the term sarcopenia.30 The group is in agreement with the EWGSOP
and IWG on the use of a cut-point for slow gait speed defined as less than 0.8 m/s, as
it is easy to measure in most settings and is highly predictive of survival and major
health outcomes.31 The cut-points established to identify weak individuals based on a
grip strength are set as less than 26 kg in men and less than 16 kg in women compared
to the EWGSOP criteria (< 30 kg in men and < 20 kg in women).32 Their criteria for
low LM is defined as an ALM < 19.75 kg for men and < 15.02 kg for women and the
criteria for low LM based on the ratio of ALM relative to body mass index (BMI) is
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defined as < 0.789 in men and < 0.512 in women.30,33 The prevalence of sarcopenia in
adults over 50 varies greatly depending on the definition being used therefore,
adoption of an operational definition is required for effective prevention and treatment
strategies to be implemented.2 A universally accepted sarcopenia definition would
allow effective interventions to be delivered to at risk individuals identified using a
variety of screening techniques for low ALM and low physical function.

Evolution of Body Composition Evaluation Techniques
Since the birth of early methods for assessing body composition, several
advancements in the techniques for providing accurate regional and total body
estimates of skeletal muscle mass have become widely available. Within a very short
time span in the early 1970s, all three contemporary clinical and reference methods,
computerized axial tomography (CT), magnetic resonance imaging (MRI), and DXA
came into existence.34 Early methods (CT and MRI) have more recently developed
into refined methods that have the ability to quantify regional and total body skeletal
muscle mass including bioelectrical impedance analysis (BIA) and DXA, all of which
have advantages and disadvantages.14
Three dimensional imaging techniques including CT and MRI have the ability
to quantify all major tissues in the human body. Computerized axial tomography
consists of a rotating x-ray tube and detector, which move in a perpendicular plane to
the subject. The difference in the attenuation or weakening of the x-rays as they
penetrate body tissues determines the density of the underlying tissues. The attenuated
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x-ray beams can then generate a computer image of the scanned area separating bone,
adipose tissue, and lean tissue. An advantage of CT is its ability to construct highquality images providing a measure of tissue composition and quality however, the
degree of radiation exposure and relatively high cost limits its use in research and
clinical settings.14 Unlike CT scanning, MRI does not use radiation; rather it creates
images from radio frequency signals emitted by hydrogen nuclei. The fundamental
MRI concept is based on interaction between nuclei of abundant hydrogen atoms and
magnetic fields produced and controlled by the system’s instrumentation. Application
of an external magnetic field followed by a pulsed radio frequency across a body part
causes the hydrogen nuclei to line up and absorb energy. When the radio wave is
turned off, the nuclei emit the energy previously absorbed thus, emitting a signal that
can then be used to create an image. While CT and MRI are accepted as accurate
measures of whole body composition, neither are available or affordable methods for
conducting sarcopenia trials.34,35
Although CT and MRI provide the most accurate assessment of body
composition, these reference methods have several limitations including expense,
equipment availability, and excessive radiation exposure with CT,36 therefore DXA
has been used more frequently due to its relatively low cost and minimal radiation
exposure.34,37 DXA uses an x-ray tube to evaluate bone mineral density and soft tissue
composition. The attenuation of the x-rays with high and low photon energies is
measurable and dependent on the thickness, density, and chemical composition of the
underlying tissue.35 The scan has the ability to evaluate fat, lean soft tissue, and bone
separately for the extremities, trunk, and other selected body regions. This segmental
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analysis can then allow estimation of ALM for assessing skeletal muscle loss with
aging.34 The availability of DXA, its modest scan cost, low radiation exposure, short
scan time, and the extensive information provided from each scan has ultimately led to
this approach being most widely used in sarcopenia research and clinical practice
today.14
While DXA is the most widely used method for assessing body composition,
the use of BIA has grown rapidly in the past two decades as a noninvasive, portable,
quick, and inexpensive alternative. Bioelectrical impedance analysis is based on the
relation between the volume of a conductor and its electrical resistance, therefore
skeletal muscle is a dominant conductor because it is an electrolyte rich tissue with
low resistance.10 The devices deliver an alternating current at one or more frequencies
via electrodes, and impedance to electrical flow is detected. Electrolyte-rich fluids
such as body water pose the least impedance to electrical flow, while lipids and bone
minerals provide the most. The traditional whole body, single frequency models have
evolved into segmental multi-frequency models which can measure resistance for each
body segment at a wide range of frequencies.38 The use of SMF-BIA has become
more common as segmental analysis of the arm and leg can be empirically calibrated
to DXA appendicular lean mass however, stable subject conditions are required for
accurate results.10,14

Comparison between BIA and DXA
Although several techniques for measuring body composition are available in
research and clinical practice, DXA is considered to be the gold standard due to its
36

precision for distinguishing fat, bone, and muscle tissue.2,39 As an alternative to CT
scans and MRI, DXA became available in 1987 as a more practical method with
limited radiation exposure.34 The ability to isolate body regions during DXA analysis
allowed many investigators the opportunity to evaluate fat, lean soft tissue, and bone
mineral content separately for the extremities, trunk, and other selected body regions.
With the introduction of portable SMF-BIA devices, the same segmental body
composition analysis could be estimated with no exposure to radiation and at a very
low cost.2,17,40 While earlier studies supported the validation of DXA using prediction
equations for the estimation of ALM, future studies would successfully validate the
use of these prediction equations by BIA.41
While studies prior to 2003 identified good correlation between BIA and MRI
using prediction equations, these equations for the estimation of ALM by BIA
compared to DXA did not yet exist. Validation of a BIA equation to predict ALM
compared to DXA was performed by Kyle et al.42 among 444 participants aged 22 to
94 years. Using a single frequency bioelectrical impedance device (SF-BIA), a single
prediction equation taking into account predictor variables including,
height2/resistance, weight, gender, age, and reactance was used for each participant.
The results indicated that DXA measured ALM was strongly correlated to the BIA
derived resistance normalized for height, and that BIA was valid for estimating ALM
with a standard error between 5% and 7.5% (1.1 kg and 1.5 kg). While several similar
prediction equations by BIA have been published and validated against DXA for the
estimation of skeletal muscle mass (SMM), general BIA prediction equations across
different ages, ethnic groups, and clinical conditions had not yet been tested.10,42,43
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The aim of a study performed by Boseaus et al.44 was to validate SF-BIA prediction
equations developed previously for estimating SMM among 86 male and 66 female
Australian patients with clinical disorders aged 70 and over compared to DXA.
Overall, the study demonstrated that SF-BIA, using a prediction equation, gave an
accurate estimate of DXA derived SMM among participants with a standard error of
1.68 kg. With the introduction of validated prediction equations for the estimation of
total SMM and ALM using BIA, several studies could then investigate the validity of
several types of single and multi-frequency BIA models among several populations
compared to DXA.
Numerous studies have investigated the validity of several bioelectrical
impedance devices for the measurement of ALM compared to DXA among several
populations with conflicting results. In a study by Leahy et al.16 in a healthy adult
population (n= 403) aged 18 to 29 years, overall agreement between SMF-BIA (Tanita
MC-180MA) and DXA for the measurement of ALM was observed. Anderson et al.17
also reported agreement between SMF-BIA (InBody720) and DXA among the 25
women aged 18 to 49 years for the estimation of ALM however, among the 25 men,
an underestimation of ALM of approximately 3.0 kg was observed.17 Another similar
study identified SMF-BIA (InBody230) as an appropriate alternative to DXA for the
estimation of fat mass, percent body fat, and total LM but not for the evaluation of
ALM among a healthy adult population between 18 and 85 years.19 While many
studies report overall agreement between SMF-BIA and DXA, there appears to be
consistent observation of a systematic bias with either overestimation or
underestimation of ALM with some devices.
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While several studies report overall agreement between several SMF-BIA
devices among healthy adult populations, others aimed to validate BIA devices among
older women. Of the studies that include older women, conflicting results regarding
the agreement between SMF-BIA and DXA specifically for the measurement of ALM
have also been observed.15,20 Buckinx et al.15 observed low agreement between SMFBIA (InBody S10) and DXA among approximately 25 women in the subcategory of
participants over the age of 65 (n= 48) using a Bland-Altman plot method. The study
reported strong agreement for LM of the upper limbs and low agreement for LM in the
lower limbs between the two techniques with a tendency for SMF-BIA to overestimate
ALM by approximately 1.75 kg.15 The participants in the subcategory over the age of
65 years were more frequently outside the limits of agreement, therefore more
participants of this age group may have been required for overall agreement to be
observed. In a similar study by Kim et al.45 a larger population of community
dwelling older men (n= 241) and women (n= 331) aged 65 to 87 years were included
to investigate the validity of SMF-BIA (InBody 720) compared to DXA. The findings
of this study compare to previous studies reporting good agreement between the two
methods for the estimation of ALM, although SMF-BIA had a tendency to
underestimate ALM among female participants with a bias of 1.59 kg (95% CI 1.49 to
1.68).45 A study by Kim et al.20 also reported agreement between SMF-BIA (InBody
720) and DXA among 129 frail community dwelling Japanese women aged 75 to 89
years.20 Kim et al.20 are the first to assess the validation of SMF-BIA for the measure
of ALM in a heterogeneous older female participant population. In order to fill the
current gap in the literature, future research efforts should investigate the accuracy of
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other SMF-BIA devices among older Caucasian women for the measurement of ALM
as a criterion for sarcopenia classification.

Conclusions
While some studies have reported overall agreement between SMF-BIA and
DXA for the estimation of ALM among older women, others have reported conflicting
results. Additional studies are required to confirm agreement between DXA and
SMF-BIA under standardized testing conditions that may reduce the systematic bias
reported by previous investigators. Despite the evidence in support of SMF-BIA
accurately estimating ALM, no study to date has investigated the agreement between
SMF-BIA and DXA among participants with characteristics of sarcopenia and/or
dynapenia based on current international definitions. Future studies investigating the
validation of SMF-BIA compared to DXA for accurate sarcopenia classification based
on established criteria for low LM based on ALM are also required. Validation of
SMF-BIA among populations of older women would provide a more portable and less
expensive alternative to DXA for clinical and epidemiological screening for
sarcopenia based on the measurement of ALM in addition to tests of physical function.
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Appendix B. Phone Screen Assessment
URI Resistance Exercise Study to Reclaim Lean Muscle and Strength (URI
RESTORE ME Project)
Data Sheet for Detailed Subject Telephone Interview

 Brief Explanation of Study
 Permission to Conduct Interview?

______Yes _______No

How did you hear about the study (if not already
recorded)?___________________________________

Name: Dr./Ms./Mrs.________________________________________________
Address: ________________________________________________________
________________________________________________________
Phone #:_________________________________________________________
E-Mail:___________________________________________________________
Best Way and Time to Contact:________________________________________

 Time Commitment – Available – Include 7-9am or 3-5pm MWF preference
________________
____Yes ____No
Wants to be contacted after ________ (Date)
Comment:___________________________________________________________
______________

 Proximity to URI
Length of commute: ______ miles or ______ minutes
Within reasonable commute_____
Willing to make unreasonable
commute______
Too far to commute______

 Age
Age: _____ yrs

Date of Birth: _____/_____/_____
MM
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DD

YY

Approximate Height: ___________ Approximate Weight: ___________ BMI:
____________

 Race
___ American Indian or Alaskan Native
___ Asian or Pacific Islander
___ Black, not of Hispanic origin
___ Hispanic
___ White, not of Hispanic origin
___ Other/Unknown

 Highest level of education completed
___ Less than high school
___ High school or GED
___ Some college
___ Two-year college degree (e.g. Associates)
___ Four-year college degree (e.g. B.S., B.A.)
___ Masters degree
___ Doctoral degree
___ Professional degree (e.g. M.D., J.D.)
___ Other (please specify) ________________________________________
 Have you attained menopause? Yes ______

No_______

If Yes, for how long? _____________________
 Smoking
Always Non-Smoker_______
Smoker________

Non-Smoker for ___________

 Physical Activity
Participates in regular (>1x/wk for past 3 months) exercise?____Yes _____No
If yes, describe in detail (e.g. frequency, intensity, duration, mode)
____________________________________________________________________
____________________________________________________________________
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____________________________________________________________________
_____________________________________________
Describe other non-structured physical activity (e.g. leisure time, gardening,
occupational, or other)
____________________________________________________________________
____________________________________________________________________
______________________________
 Cardiovascular (heart, blood, or blood vessel) conditions?
____No ____Yes (Record on Medical History/Treatment Form)
Comments:_____________________________________________________
______________________________________________________________

 Respiratory Conditions?
____No ____Yes (Record on Medical History/Treatment Form)
Comments:_____________________________________________________
______________________________________________________________

 Osteoarthritis/Degenerative Arthritis
___No ___Yes
If yes, how long and what was the
severity________________________________________________________
____________________________________

 High Blood Pressure
No_____
Yes_____ Controlled (Record High BP and Treatment on Medical
History/Treatment Form)
Yes_____ Uncontrolled
Comments:________________________________________________________
_________________________________________________________________
______________________________

 Orthopedic conditions (knee, neck, or other back pain)
___No
___Yes
If yes, describe in detail including severity
______________________________________________________________
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______________________________________________________________
______________________________

 Diabetes
_____No
_____Yes – Type 2. If type 2, taking insulin now?
_______________________
_____Yes – Type 1 (Insulin Dependent)
Comments:____________________________________________________
_____________________________________________________________

 Any major surgeries as an adult?
___No
___Yes
If yes, what type (e.g. surgeries of the joints, heart surgeries, angioplasty,
bypass surgery, pacemakers, etc.) and date(s)
______________________________________________________________
______________________________________________________________
______________________________________________________________
_____________________________________________

 Other Medical Conditions (especially those that would make exercise difficult
or unsafe)
_____No
_____Yes (Record on Medical History/Treatment Form)
Comments:_____________________________________________________
______________________________________________________________
___________________________

 Medication Info – See last page
_____No
_____Yes (Record on Medical History/Treatment Form)
Comments:_____________________________________________________
______________________________________________________________
___________________________
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 Personal Physician Info
Name of Physician:
______________________________________________________
Specialty of Physician:
____________________________________________________
Phone Number:_______________________________________
Fax Number:_________________________________________
Address (if phone and fax unknown):

 Summary
Interviewer Printed Name: ______________________________________

Interviewer Signature:

______________________________________

Questions/Comments:___________________________________

Reviewer Initials: ______

_____Appears to Qualify

_____Need More Information

_____Needs Drs. Delmonico, Hatfield, Xu, or Lofgren to review
_____ Not Qualified

Questions/Comments:
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Appendix D. Medical History
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Appendix E. Baseline Data Collection Sheet

URI RESTORE ME Study Data Sheet
BaselineTesting Day 1
Participant ID #:
Measurements

Date:
Baseline Testing Day 1

Initial

Resting Heart Rate 1 (bpm)
Resting Heart Rate 2 (bpm)
Resting Blood Pressure 1
Resting Blood Pressure 2

Grip Strength (kilograms)
Dynamometer Setting:

Best Grip Trial:

Grip R1:

Grip L1:

Grip R2:
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Grip L2:

Baseline Testing Day 1
Participant ID#:

Date:

SPPB









BALANCE SCORING:
A. Side-by-side-stand
o Held for 10 sec ❒
1 point
o Not held for 10 sec ❒
0 points
o Number of seconds held if less than 10 sec:____sec
o Not attempted ❒
0 points
o If participant did not attempt test or failed, check why:
o Participant could not walk unassisted ❒
o Not attempted, you felt unsafe ❒
o Not attempted, participant felt unsafe❒
o Participant unable to understand instructions ❒
o Other (Specify) ❒
o Participant refused ❒
o If 0 points, end Balance Tests
B. Semi-Tandem Stand
o Held for 10 sec ❒
1 point
o Not held for 10 sec ❒
0 points
o Number of seconds held if less than 10 sec:____sec
o Not attempted ❒
0 points
o If participant did not attempt test or failed, check why:
o Participant could not walk unassisted ❒
o Not attempted, you felt unsafe ❒
o Not attempted, participant felt unsafe❒
o Participant unable to understand instructions ❒
o Other (Specify) ❒
o Participant refused ❒
o If 0 points, end Balance Tests
C. Tandem Stand
o Held for 10 sec ❒
2 points
o Held for 3 to 9.99 sec ❒
1 point
o Held for < than 3 sec ❒
0 points
o Not attempted ❒
0 points
o If participant did not attempt test or failed, check why:
o Participant could not walk unassisted ❒
o Not attempted, you felt unsafe ❒
o Not attempted, participant felt unsafe❒
o Participant unable to understand instructions ❒
o Other (Specify) ❒
o Participant refused ❒
D. Total Balance Tests score ______(sum points)
For 4-Meter Walk:
o If time is more than 8.70 sec: ❒
1 point
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If time is 6.21 to 8.70 sec: ❒
2 points
If time is 4.82 to 6.20 sec: ❒
3 points
If time is less than 4.82 sec: ❒
4 points
CHAIR SCORING:
Single Chair Stand Test:
o Safe to stand without help YES ❒NO ❒
o Participant stood without using arms YES ❒NO ❒
If yes go to repeated stand
o Participant used arms to stand YES ❒
NO ❒
If yes end test; score as 0 points
o Test not completed ❒
End test; score as 0 points
o If participant did not attempt test or failed, check why:
o Tried but unable ❒
o Participant could not walk unassisted ❒
o Not attempted, you felt unsafe ❒
o Not attempted, participant felt unsafe❒
o Participant unable to understand instructions ❒
o Other (Specify) ❒
o Participant refused ❒
o
o
o





Repeated Chair Stand Test
o Safe to stand five times Yes❒ No❒If five stands completed record time
o Time to complete five stands ___sec
o If participant did not attempt test or failed, circle why:
o Tried but unable ❒
o Participant could not walk unassisted ❒
o Not attempted, you felt unsafe ❒
o Not attempted, participant felt unsafe❒
o Participant unable to understand instructions❒
o Other (Specify) ❒
o Participant refused ❒



Scoring the Repeated Chair Test
o Participant unable to complete 5 chair stands or completes stands in >60 sec: ❒
0 points
o If chair stand time is 16.70 sec or more: ❒1 points
o If chair stand time is 13.70 to 16.69 sec: ❒2 points
o If chair stand time is 11.20 to 13.69 sec: ❒3 points
o If chair stand time is 11.19 sec or less: ❒4 points







Scoring for Complete Short Physical Performance Battery
Total Balance Test score _____ points
Gait Speed Test score _____ points
Chair Stand Test score _____ points
Total Score _____ points (sum of points above)
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Test

Result

Date Completed

400m walk
(sec)
SPPB

points scored

Single Leg
Stand, 10 sec
Sit and Reach
(+/- cm)
Timed Up
and Go 1
(sec)
Timed Up
and Go 2
(sec)
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Initial

Baseline Testing
Participant ID #:

Measurements

Date:

Date

Initial

Resting Heart Rate 1 (bpm)
Resting Heart Rate 2 (bpm)
Resting Blood Pressure 1
Resting Blood Pressure 2
Blood Draw 1

Anthropometrics

Measurement
1

Measurement
2

Height (inches)
Weight (lbs)
Waist
Circumference
(inches)
Hip
Circumference
(inches)
BMI (kg/m2)

Waist to Hip
Ratio

Notes:
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Average

Initial

Baseline Testing
Participant ID#:
Measurements

Date:
Baseline Testing Day 1

Initial

Resting Heart Rate 1
(bpm)
Resting Heart Rate 2
(bpm)
Resting Blood Pressure
1
Resting Blood Pressure
2
Blood Draw 2

Results collected

Date

Initial

DEXA

Date:

In-Body: BIA
Voided Bladder

Yes

Height:

Weight:

BMI:

R Arm LM:

L Arm LM:

R Leg LM:
Total ALM:
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No

L Leg LM:

Appendix F. Yale Physical Activity Survey
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Appendix G. Dietary Screening Tool

DIRECTIONS: Please check one response to each question that best describes how
you eat.
How often do you usually eat fruit as a snack?
____ Never
____ Less than once a week
____ 1 or 2 times a week
____ 3 or more times a week
How often do you usually eat whole grain breads?
____ Never or less than once a week
____ 1 or 2 times a week
____ 3 or more times a week
How often do you usually eat whole grain cereals?
____ Never or less than once a week
____ 1 or 2 times a week
____ 3 or more times a week
How often do you usually eat candy or chocolate?
____ Never
____ Less than once a week
____ 1 or 2 times a week
____ 3 or more times a week
How often do you eat crackers, pretzels, chips, or popcorn?
____ Never
____ Less than once a week
____ 1 or 2 times a week
____ 3 or more times a week
How often do you eat cakes or pies?
____ Never
____ Less than once a week
____ 1 or 2 times a week
____ 3 or more times a week
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How often do you eat cookies?
____ Never
____ Less than once a week
____ 1 or 2 times a week
____ 3 or more times a week
How often do you eat ice cream?
____ Never
____ Less than once a week
____ 1 or 2 times a week
____ 3 or more times a week
How often do you eat cold cuts, hot dogs, lunchmeats or deli meats?
____ Never or less than once a week
____ 1 or 2 times a week
____ 3 or more times a week
How often do you eat bacon or sausage?
____ Never or less than once a week
____ 1 or 2 times a week
____ 3 or more times a week
How often do you eat carrots, sweet potatoes, broccoli, or spinach?
____ Never
____ Less than once a week
____ 1 or 2 times a week
____ 3 or more times a week
How often do you eat fruit (not including juice)? Please include fresh, canned or
frozen fruit.
____ Never or Less than once a week
____ 1 or 2 times a week
____ 3 to 5 times a week
____ Every day or almost every day
How often do you eat hot or cold breakfast cereal?
____ Never
____ Less than once a week
____ 1 or 2 times a week
____ 3 to 5 times a week
____ Every day or almost every day
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How often do you drink some kind of juice at breakfast?
____ Never or Less than once a week
____ 1 or 2 times a week
____ 3 to 5 times a week
____ Every day or almost every day
How often do you eat chicken or turkey?
____ Never or less than once a week
____ 1 or 2 times a week
____ More than 3 times a week
How often do you drink a glass of milk?
____ Never or Less than once a week
____ 1 or 2 times a week
____ 3 to 5 times a week
____ Every day or almost every day
____ More than once every day
Do you usually add butter or margarine to foods like bread, rolls, or biscuits?
____ Yes
____ No
Do you usually add fat (butter, margarine or oil) to potatoes and other
vegetables?
____ Yes
____ No
Do you use gravy (when available) at meals?
____ Yes
____ No
Do you usually add sugar or honey to sweeten your coffee or tea?
____ Yes
____ No
Do you usually drink wine, beer or other alcoholic beverages?
____ Yes
____ No
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How often do you eat fish or seafood that IS NOT fried?
____ Never
____ Less than once a week
____ Once a week
____ More than once a week
How many servings of milk, cheese, or yogurt do you usually have each DAY?
____ None
____ One
____ Two or more
How many different vegetable servings do you usually have at your main meal of
the day?
____ None
____ One
____ Two
____ Three or more
Which of the following best describes your nutritional supplement use?
____ I don’t use supplements
____ I use supplements other than vitamins and mineral
____ I use a multivitamin/mineral preparation (e.g. Centrum)
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